Jan 11 (Reuters) - Aradigm Corp:
* ARADIGM REPORTS RESULTS OF FDA ADVISORY COMMITTEE MEETING ON LINHALIQ‍​
* ARADIGM CORP - ‍FDA HAS SET A PDUFA ACTION DATE OF JANUARY 26, 2018 FOR COMPLETION OF ITS REVIEW OF LINHALIQ​
* ARADIGM CORP - ‍FDA ADAC DID NOT RECOMMEND APPROVAL FOR LINHALIQ AS A TREATMENT FOR NCFBE PATIENTS WITH CHRONIC LUNG PSEUDOMONAS AERUGINOSA INFECTIONS​
* ARADIGM - ADAC VOTED 12 “NO” TO 3 “YES”, 1 ABSTENTION, ON QUESTION OF CO‘S PROVISION OF EVIDENCE OF SAFETY & EFFICACY OF CIPROFLOXACIN DISPERSION Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.